These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29037993)

  • 1. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
    Casale TB; Win PH; Bernstein JA; Rosén K; Holden M; Iqbal A; Trzaskoma BL; Yang M; Antonova EN; Murphy T; Scarupa MD; Sofen H; Kaplan A
    J Am Acad Dermatol; 2018 Apr; 78(4):793-795. PubMed ID: 29037993
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab use during pregnancy for CIU: a tertiary care experience.
    Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
    Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
    Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):598-606. PubMed ID: 29952712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
    Finlay AY; Kaplan AP; Beck LA; Antonova EN; Balp MM; Zazzali J; Khalil S; Maurer M
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1715-1721. PubMed ID: 28573683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
    Tharp MD; Bernstein JA; Kavati A; Ortiz B; MacDonald K; Denhaerynck K; Abraham I; Lee CS
    JAMA Dermatol; 2019 Jan; 155(1):29-38. PubMed ID: 30427977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.
    Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
    Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
    Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
    Casale TB; Murphy TR; Holden M; Rajput Y; Yoo B; Bernstein JA
    J Allergy Clin Immunol Pract; 2019; 7(7):2487-2490.e1. PubMed ID: 31034999
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.
    Metz M; Schütz A; Weller K; Gorczyza M; Zimmer S; Staubach P; Merk HF; Maurer M
    J Allergy Clin Immunol; 2017 Sep; 140(3):864-867.e5. PubMed ID: 28389393
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
    Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Goldstein S; Gabriel S; Kianifard F; Ortiz B; Skoner DP
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):500-504. PubMed ID: 28390587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
    Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
    J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab.
    Ossorio-García L; Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Linares-Barrios M
    Clin Exp Dermatol; 2016 Dec; 41(8):929-930. PubMed ID: 27761937
    [No Abstract]   [Full Text] [Related]  

  • 18. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
    Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
    Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria.
    Türk M; Kocatürk E; Cüre K; Yılmaz İ
    J Allergy Clin Immunol Pract; 2018; 6(4):1389-1390. PubMed ID: 29410306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.